ReviewWorld journal of surgical oncology2021
Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: a review.
Review in World journal of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Meta-analysis of the value of albumin-bilirubin grading on changes in liver function and its prognostic assessment in patients with hepatocellular carcinoma treated with transhepatic arterial chemoembolization.World journal of surgical oncology · 2025Pooled it
- Comparison of the efficacy and safety of repeated hepatectomy and radiofrequency ablation in the treatment of primary recurrent liver cancer: a meta-analysis.World journal of surgical oncology · 2022Pooled it
- Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus.Frontiers in oncology · 2026Article
- Efficacy and safety of Yangxiao Fukang granule in the treatment of stage Ⅲ hepatitis B related liver cancer: study protocol for a randomized controlled trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Clinical value of systemic immunoinflammatory index in predicting recurrence and metastasis in patients with primary liver cancer.BMC gastroenterology · 2025Article
- Chitosan-based biomaterial delivery strategies for hepatocellular carcinoma.Frontiers in pharmacology · 2024Review
- ALPPS versus portal vein embolization for hepatitis B virus-associated hepatocellular carcinoma: a delicate balance between volume and morbidity.Hepatobiliary surgery and nutrition · 2023Article
- Recent therapeutics in hepatocellular carcinoma.American journal of cancer research · 2023Review
- Comparison of efficacy and safety between transarterial chemoembolization (TACE) combined with lenvatinib versus TACE combined with sorafenib in the treatment of intermediate and advanced hepatocellular carcinoma.American journal of translational research · 2023Article
- A systematic review and meta-analysis on the efficacy and safety of transcatheter arterial chemoembolization combined with radiofrequency ablation in the treatment of primary liver cancer.Translational cancer research · 2022Article
- Intended preoperative trans-arterial embolization for large hepatocellular carcinoma: a retrospective cohort study.World journal of surgical oncology · 2022Article
- Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis.World journal of surgical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTranscatheter arterial chemoembolization has been widely used in patients with hepatocellular carcinoma. However, double blood supply and the existence of portal vein tumor thrombus influence the efficacy of transcatheter arterial chemoembolization. MAIN BODY: Theoretically, portal vein embolization combined with transcatheter arterial chemoembolization may bring a breakthrough in the therapeutic effect of hepatocellular carcinoma. The feasibility, efficacy, long-term survival benefits, and side effects of the combined treatment have been explored in previous studies. Chemotherapeutic agents may also be added in the portal vein embolization procedure to further improve the treatment response.
conclusionIn this study, we review the existing data and studies on the combined treatment in patients with hepatocellular carcinoma and provide an overall view of the strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.